Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

Ozguroglu, Mustafa; Sezer, Ahmet; Kilickap, Saadettin; Gumus, Mahmut; Bondarenko, Igor; Gogishvili, Miranda; Turk, Haci M.; Cicin, Irfan; Bentsion, Dmitry; Gladkov, Oleg; Clingan, Philip R.; Sriuranpong, Virote; Rizvi, Naiyer A.; McGinniss, Jennifer; Pouliot, Jean-Francois; Lee, Sue; Seebach, Frank A.; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra

Publication:
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

dc.contributor.author	Ozguroglu, Mustafa
dc.contributor.author	Sezer, Ahmet
dc.contributor.author	Kilickap, Saadettin
dc.contributor.author	Gumus, Mahmut
dc.contributor.author	Bondarenko, Igor
dc.contributor.author	Gogishvili, Miranda
dc.contributor.author	Turk, Haci M.
dc.contributor.author	Cicin, Irfan
dc.contributor.author	Bentsion, Dmitry
dc.contributor.author	Gladkov, Oleg
dc.contributor.author	Clingan, Philip R.
dc.contributor.author	Sriuranpong, Virote
dc.contributor.author	Rizvi, Naiyer A.
dc.contributor.author	McGinniss, Jennifer
dc.contributor.author	Pouliot, Jean-Francois
dc.contributor.author	Lee, Sue
dc.contributor.author	Seebach, Frank A.
dc.contributor.author	Lowy, Israel
dc.contributor.author	Gullo, Giuseppe
dc.contributor.author	Rietschel, Petra
dc.date.accessioned	2021-11-30T20:59:15Z
dc.date.available	2021-11-30T20:59:15Z
dc.date.issued	2021-05-01T00:00:00Z
dc.identifier.citation	Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.doi	10.1200/jco.2021.39.15_suppl.9085
dc.identifier.uri	http://hdl.handle.net/20.500.12645/29668
dc.identifier.wos	WOS:000708120605064
dc.title	Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
dc.type	Article
dspace.entity.type	Publication
local.avesis.id	14f44025-8fbb-4351-aa07-8eb5879f5e2a
local.publication.goal	03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational	1
relation.isGoalOfPublication	9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery	9c198c48-b603-4e2f-8366-04edcfc1224c

Collections

Yayınlar - Eserler

Publication: Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

Files

Collections

Publication:
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.